KEKSA BEMORLARDA YURAK YETISHMOVCHILIGINI ANIQLASHGA OID PROTEOMIK PROFILLASH

Maqola yon paneli

pdf (inglizcha)
Nashr qilingan: 2024-02-05
DOI: https://doi.org/10.66073/researchfocus.v3i1.764
Kalit so‘zlar:
Epidemiologiya, Yurak yetishmovchiligi, Chap qorincha disfunksiyasi, Xavfni bashorat qilish, Proteomika va biomarkerlar

Maqolaning asosiy mazmuni

Yuldashev Soatboy Jiyanboevich
Tibbiyot fanlari nomzodi, dotsent, kafedra mudiri
Imran Aslam
PhD, farmakologiya kafedrasi
Jiyanboyev Nodirbek Soatboyevich
Buxoro tibbiyot fanlari universiteti davolash fakulteti 5-kurs talabasi

Abstrak

Maqsad. Ushbu sakson oqsil ilgari yurak-qon tomir patologiyasi bilan bog'liq deb aniqlangan bo'lib, ushbu tadqiqot ishining maqsadi yurak yetishmovchiligi yoki umuman yurak yetishmovchiligining yangi xavf omillarini topish uchun mazkur oqsillarni proteomik profillashdan foydalanishdir. Materiallar va usullar. Yaqinlikni kengaytirish tahlili (proteomik profillash) yurak yetishmovchiligi bo'lmagan holatda boshlang'ich bosqichda keksa yoshdagi turli kogortalarga ega ikki xil jamoada o'tkazildi. Prospektiv tadqiqotlar sifatida Qon tomir tizimini prospektiv o'rganish (PIV) va Katta yoshli erkaklarni longitudinal o'rganish (LSAM) tanlangan bo'lib, ularning mos qiymatlari (80 hodisa, yoshning medianasi = 70,2 yil, n = 901) va (90 hodisa, yoshning medianasi = 77,8 yil, n = 685) ni tashkil etdi. PIV da jins va yoshga tuzatish kiritilgan holda kuzatilganidek, yurak yetishmovchiligining yuzaga kelishi 29 ta oqsil bilan bog'liq edi. Tuzatishlar ko'p sonli testlardan so'ng kiritildi. LSAM da yurak yetishmovchiligi bilan bog'liq 18 ta oqsil aniqlandi. Har ikkala kogortada 9 ta oqsilning yuqori darajasi yurak yetishmovchiligining yuzaga kelishi bilan bog'liq bo'ldi. Belgilangan xavf omillariga qo'shimcha tuzatishlar kiritildi. Chap qorincha sistolik funksiyasining yetishmovchiligi aniqlanib, u o'sish differensiatsiyasi omili 15 (GDF-15), urokinaza turidagi plazminogen aktivatorining yuza retseptori (U-PAR), matriks metalloproteinaza-12 (MMP-12), o'sma nekrozi omili bilan bog'liq apoptozni keltirib chiqaruvchi ligand retseptori 2 (TRAIL-R2), spondin-1 (SPON1) va follistatin (FS) mavjudligi bilan bog'liq ekani ko'rsatildi. Bu exokardiografik kuzatuv orqali aniqlandi. Barcha P qiymatlari 0,02 dan past edi. Natijalar. PIV ning yakuniy tavsiflari jami 901 nafar ishtirokchi orasida yoshning medianasi 70 yil ekanini o'z ichiga oldi. LSAM da tavsif 685 nafar ishtirokchi orasida yoshning medianasi 78 yil ekanini ko'rsatdi. PIV da kuzatuv davrida yosh oralig'i 0,1-10,9 yilni tashkil etib, medianasi 10 yil bo'ldi, yurak yetishmovchiligi sababli 80 marta kasalxonaga yotqizish qayd etildi, yurak yetishmovchiligi darajasi esa 100 kishiga 0,96 ni tashkil qildi. LSAM da yurak yetishmovchiligi sababli 90 marta kasalxonaga yotqizish bo'lib, yosh oralig'i 0,2-10,9 yilni, medianasi 8 yilni tashkil etdi, yurak yetishmovchiligi darajasi esa 100 kishiga 1,83 ni tashkil qildi. PIV da soxta topilmalar darajasi 5% bo'lib, jins va yoshga tuzatish kiritilgandan so'ng 29 ta oqsil bilan bog'liqlik aniqlandi. LSAM da 18 ta oqsilning yurak yetishmovchiligi yuzaga kelishi bilan bog'liqligi nominal edi. Xulosa. Keksalar orasida o'tkazilgan ushbu tadqiqotda proteomik profillash orqali oqsillarning fibrinoliz, apoptoz, yallig'lanish, matriksni qayta shakllantirish va yurak yetishmovchiligidagi ishtirokiga oid bir qancha yangi bog'liqliklar aniqlandi. Ushbu tadqiqot natijalari asosiy mexanizmlar va klinik qo'llanilishni o'rgangan boshqa tadqiqotlarga ham mos keladi.

Maqola tafsilotlari

Nashr

Jild 3 Nomeri 1 (2024): Research Focus International Scientific Journal. 3-tom, 1-son (2024)

Bo'lim

14.00.00 – Tibbiyot fanlari
Creative Commons litsenziyasi

Ushbu asar Creative Commons Attribution 4.0 International litsenziyasi asosida litsenziyalangan.

Qanday iqtibos keltirish kerak

KEKSA BEMORLARDA YURAK YETISHMOVCHILIGINI ANIQLASHGA OID PROTEOMIK PROFILLASH. (2024). Research Focus International Scientific Journal, 3(1), 198-203. https://doi.org/10.66073/researchfocus.v3i1.764

Adabiyotlar

Arterioscler Thromb Vasc Biol 2005;25:2368–2375. Hedstrand H. A study of middle-aged men with particular reference to risk factors for cardiovascular disease. Ups J Med Sci Suppl 1975; 19:1–61.

Borne Y, Persson M, Melander O, Smith JG, Engstrom G. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail 2014; 16:377–383.

Clemitson JR, Dixon RJ, Haines S, Bingham AJ, Patel BR, Hall L, Lo M, Sassard J, Charchar FJ, Samani NJ. Genetic dissection of a blood pressure quantitative trait locus on rat chromosome 1 and gene expression analysis identifies SPON1 as a novel candidate hypertension gene. Circ Res 2007;100: 992–999.

Echouffo-Tcheugui JB, Greene SJ, Papadimitriou L, Zannad F, Yancy CW, Gheorghiade M, Butler J. Population risk prediction models for incident heart failure: a systematic review. Circ Heart Fail 2015;8:438–447.

Helske S, Kovanen PT, Lindstedt KA, Lommi J, Turto H, Werkkala K, Kupari M. Increased osteoprotegerin and decreased RANKL associate with the severity of heart failure in patients with aortic stenosis. Circulation 2005; 112: U818–U.

Hong Y, XieW, Chen CS. Effect of shengmai injection on TRAIL death receptor of patients with congestive heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005; 25:1092–1095.

Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study.

Lind L, Ärnlöv J, Lindahl B, Siegbahn A, Sundström J, Ingelsson E. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. Atherosclerosis 2015;242:205–210.

Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 2013;8:1551–1566.

McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998;19 Suppl P: P9–P16.

Willingale R, Jones DJ, Lamb JH, Quinn P, Farmer PB, Ng LL. Searching for biomarkers of heart failure in the mass spectra of blood plasma. Proteomics 2006; 6:5903–5914.

Aslam, I., Asadullah, R. N. A., Akhlaq, F., Ali, A., & Fatima, A. (2023). Diabetic Disease and its 2-4 Fold Mortality Rate, Patients Getting Standard Therapy in the Modern ERA of CVD Risk Reduction. Pakistan Journal of Medical & Health Sciences, 17(01), 420-420.

Rajabboevna, A. R., & Yangiboyevna, N. S. (2023). EPILEPSIYA BILAN OG'RIGAN BEMORLARDA TOPAMAX DORI VOSITASINING KLINIK VA FARMAKOEKONOMIK ASPEKTLARINING SAMARADORLIGINI BAHOLASH. Research Focus International Scientific Journal, 2(5), 198-202.

Jiyanboyevich, Y. S., Aslam, I., Ravshanovna, M. U., Azamatovna, F. G., & Murodovna, J. D. (2021). Ventricular Arrhythmias With Congenital Heart Disease Causing Sudden Death. NVEO-NATURAL VOLATILES & ESSENTIAL OILS Journal| NVEO, 2055-2063.